×

AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy

By Thomson Reuters Nov 16, 2026 | 2:02 AM

Nov 16 (Reuters) – AstraZeneca said on Monday it has won two US drug approvals, an expanded bladder ​cancer use for its immunotherapy ‌Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.

• The US Food and Drug Administration approved Imfinzi, combined with enfortumab ‌vedotin, ​a targeted therapy prior ⁠to surgery, for ⁠muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy

• The Imfinzi approval was based on ​a late-stage trial which showed the regimen cut the risk of ⁠cancer recurrence by ⁠49% and the risk of ​death by 42%

• Imfinzi is already approved ​across more than 50 countries and ‌is indicated for a range of cancers including lung and bladder

• The FDA also approved Klygefa, developed by ⁠AstraZeneca’s rare disease unit Alexion, for adults with generalised myasthenia gravis who carry antibodies that ⁠attack proteins ‌on the nerves, disrupting ⁠communication with muscles

• Klygefa also ​won ‌approval in the EU for ​the same ⁠indication on Monday, adding to its clearances in Japan and other countries for certain adults with gMG

(Reporting by Raechel Thankam Job in Bengaluru; Editing by ​Janane Venkatraman)